2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5130 TP53-mutated acute myeloid leukemia is associated with increased pretreatment infection and infection-related treatment omission

Xiaojing Lin Sr, PhD, Ya Li, MD2, Leilei Wu, MS3, Qing Xue, PhD4, Yuncan Cao, MD5, Jiong Hu, MD6, Yang Shen, PhD7, Hongming Zhu8
1 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
3 Yancheng Third People’s Hospital, Jiangsu, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medica Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China

Introduction: TP53-mutated acute myeloid leukemia (AML) is associated with an exceptionally poor prognosis and a high risk of relapse. Although these outcomes have largely been attributed to resistance to anti-leukemic therapy and relapse-related disease biology, clinical observations suggest that a high burden of infection at initial presentation may also contribute. Severe pretreatment infections can delay or preclude timely initiation of intensive therapy, or necessitate treatment-intensity reduction. This increased susceptibility to infection may, in part, reflect the immunosuppressive consequences of biologically aggressive disease. To investigate whether pretreatment infection burden represents a clinical contributor to the adverse outcomes of TP53-mutated AML, we compared these patients with TP53-wild-type patients also classified as adverse risk according to the 2022 European LeukemiaNet (ELN) recommendations, evaluating infection patterns and infection-related treatment disruption.

Methods: We conducted an IRB-approved, single-center retrospective study from June 1, 2019, to June 1, 2026, with waiver of informed consent. Pretreatment infection was defined from 7 days before admission through initiation of first AML-directed therapy. Patients with relapsed/refractory disease, noninitial treatment admissions, acute promyelocytic leukemia, or insufficient infection data were excluded. TP53-mutated AML was compared with TP53-wild-type, ELN adverse-risk AML. Fisher exact tests were used to estimate unadjusted odds ratios (ORs), and logistic regression adjusted for age and sex. Nonlinear age effects were evaluated using natural cubic splines; age-stratified analyses used 60 years as the cutoff and included a TP53-by-age interaction test. Among infected patients, manually reviewed clinical records were used to classify pulmonary/respiratory, bloodstream/systemic, invasive fungal infection signals, multisite infection, documented pathogens, and infection-related treatment effects. Molecular subgroup analyses were exploratory.

Results: The cohort included 602 patients: 146 with TP53-mutated AML and 456 with TP53-wild-type, ELN adverse-risk AML. Pretreatment infection occurred in 72/146 (49.3%) versus 158/456 (34.6%), respectively (unadjusted OR, 1.83; 95% CI, 1.23–2.72; P = .002). The association remained significant after adjustment for age and sex (adjusted OR, 1.84; 95% CI, 1.26–2.70; P = .002) and after nonlinear modeling of age (adjusted OR, 1.84; P = .002). Among patients younger than 60 years, infection rates were 55.8% versus 34.8% (OR, 2.35; P = .007); among those aged 60 years or older, rates were 45.7% versus 34.5% (OR, 1.60; P = .077). There was no evidence of effect modification by age (P-interaction = .332). Among infected patients, pulmonary/respiratory infection occurred in 62.5% versus 62.0%, bloodstream/systemic infection in 13.9% versus 10.8%, invasive fungal infection signals in 5.6% versus 7.6%, and multisite infection in 13.9% versus 23.4%; none differed significantly. A pathogen was documented in 19.4% versus 31.0% (OR, 0.54; P = .080). TP53-mutated patients were less often classified as having treatment delay (13.9% vs 35.4%; OR, 0.30; P = .001) but were more likely to receive no AML-directed treatment because of infection (16.7% vs 6.3%; OR, 2.94; P = .027). Treatment interruption or intensity reduction was similar (9.7% vs 9.5%; P = 1.00). Within TP53-mutated AML, variant allele frequency ≥50% was associated with higher infection prevalence (56.5% vs 39.0%; adjusted OR, 2.09; 95% CI, 1.04–4.17; P = .037), whereas multi-hit status was not. No gene-level association within the TP53-wild-type ELN adverse-risk group remained significant after false discovery rate correction.
Conclusions: Compared with TP53-wild-type patients in the same ELN 2022 adverse-risk category, patients with TP53-mutated AML had a significantly higher prevalence of infection before initial AML therapy. This association remained significant after adjustment for age and sex, with no evidence of effect modification by age. Among patients with pretreatment infection, TP53-mutated patients were also more likely to receive no AML-directed treatment because of infection. The high pretreatment infection burden may be related to an immunosuppressive bone marrow microenvironment and the aggressive clinical presentation of TP53-mutated AML; these potential mechanisms warrant further investigation.



Xiaojing Lin Sr, PhD: No relevant conflicts of interest to declare.